Home LiteratureArticle Details
PMID: 15560976 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

Current opinion in biotechnology ·Vol. 15 ·No. 6 ·2004-12-00 ·Pages 506-12

Drexler I, Staib C, Sutter G

Abstract

Safety-tested modified vaccinia virus Ankara (MVA) has been established as a potent vector system for the development of candidate recombinant vaccines. The versatility of the vector system was recently demonstrated by the rapid production of experimental MVA vaccines for immunization against severe acute respiratory syndrome associated coronavirus. Promising results were also obtained in the delivery of Epstein-Barr virus or human cytomegalovirus antigens and from the clinical testing of MVA vectors for vaccination against immunodeficiency virus, papilloma virus, Plasmodium falciparum or melanoma. Moreover, MVA is considered to be a prime candidate vaccine for safer protection against orthopoxvirus infections. Thus, vector development to challenge dilemmas in vaccinology or immunization against poxvirus bio-threat seems possible, yet the right choice should be made for a most beneficial use.

MeSH Terms
Animals Antigens/genetics,metabolism Genetic Engineering Genetic Vectors Humans Smallpox Vaccine Vaccines Vaccinia virus
Chemicals
Antigens Smallpox Vaccine Vaccines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Drexler Ingo
Institute for Molecular Virology, München, Germany.
Staib Caroline
Sutter Gerd
References (57)
57 references, click to expand
  1. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Virology. 2002 Mar 15;294(2):270-81 PMID: 12009868
  2. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
    J Immunol. 2004 May 15;172(10):6209-20 PMID: 15128809
  3. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.
    J Virol. 2000 Aug;74(16):7651-5 PMID: 10906221
  4. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus.
    J Immunol. 2004 Mar 1;172(5):3094-100 PMID: 14978115
  5. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A.
    Infect Immun. 2002 Mar;70(3):1623-6 PMID: 11854254
  6. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
    Cancer Res. 1999 Oct 1;59(19):4955-63 PMID: 10519409
  7. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
    Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6 PMID: 15096611
  8. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge.
    J Gen Virol. 2004 May;85(Pt 5):1191-1201 PMID: 15105535
  9. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.
    Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63 PMID: 12869693
  10. Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.
    Clin Diagn Lab Immunol. 2004 Mar;11(2):406-10 PMID: 15013995
  11. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    J Immunol. 2003 Mar 15;170(6):3401-7 PMID: 12626601
  12. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
    J Gen Virol. 2003 Feb;84(Pt 2):361-368 PMID: 12560568
  13. Duration of antiviral immunity after smallpox vaccination.
    Nat Med. 2003 Sep;9(9):1131-7 PMID: 12925846
  14. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Cancer Res. 2003 Nov 15;63(22):7942-9 PMID: 14633725
  15. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
    Clin Cancer Res. 2004 Aug 15;10(16):5381-90 PMID: 15328176
  16. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    J Immunol. 2004 Mar 15;172(6):3745-57 PMID: 15004179
  17. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.
    Vaccine. 2003 Dec 8;22(1):21-9 PMID: 14604567
  18. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    J Virol. 2004 Jan;78(2):768-78 PMID: 14694109
  19. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
    Nature. 2004 Mar 11;428(6979):182-5 PMID: 15014500
  20. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.
    Blood. 2004 Aug 1;104(3):847-56 PMID: 15090456
  21. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
    J Virol. 2002 Aug;76(15):7625-31 PMID: 12097576
  22. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.
    J Virol. 2003 Aug;77(15):8394-407 PMID: 12857909
  23. Improved host range selection for recombinant modified vaccinia virus Ankara.
    Biotechniques. 2003 Apr;34(4):694-6, 698, 700 PMID: 12703290
  24. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Science. 2001 Apr 6;292(5514):69-74 PMID: 11393868
  25. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
    J Gen Virol. 2004 Apr;85(Pt 4):911-919 PMID: 15039533
  26. Differences between T cell epitopes recognized after immunization and after infection.
    J Immunol. 2002 Oct 15;169(8):4511-21 PMID: 12370388
  27. Nonreplicating vaccinia vector efficiently expresses recombinant genes.
    Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51 PMID: 1438287
  28. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.
    J Virol. 2002 Apr;76(8):4108-12 PMID: 11907251
  29. Monitoring of human immunological responses to vaccinia virus.
    Methods Mol Biol. 2004;269:243-66 PMID: 15114020
  30. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.
    J Virol. 2002 Apr;76(7):3329-37 PMID: 11884558
  31. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    J Virol. 2004 Apr;78(8):3965-76 PMID: 15047812
  32. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
    J Virol. 2003 Jun;77(12):7048-57 PMID: 12768024
  33. Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus.
    Hum Gene Ther. 2002 Jun 10;13(9):1127-40 PMID: 12067445
  34. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
    J Virol. 2002 Jul;76(14):7187-202 PMID: 12072518
  35. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    J Immunol. 2003 Aug 1;171(3):1602-9 PMID: 12874255
  36. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
    J Gene Med. 2003 Aug;5(8):690-9 PMID: 12898638
  37. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
    Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71 PMID: 14529359
  38. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.
    J Virol. 2003 Feb;77(4):2400-9 PMID: 12551977
  39. Construction and isolation of recombinant MVA.
    Methods Mol Biol. 2004;269:77-100 PMID: 15114009
  40. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection.
    J Immunol. 2004 Feb 15;172(4):2256-64 PMID: 14764694
  41. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5 PMID: 15070762
  42. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
    Mol Cancer Ther. 2002 Oct;1(12):1129-37 PMID: 12481437
  43. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
    J Infect Dis. 2003 Oct 15;188(8):1239-44 PMID: 14551895
  44. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.
    J Virol. 2004 May;78(9):4433-43 PMID: 15078924
  45. Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
    Hum Gene Ther. 2003 Sep 20;14(14):1347-60 PMID: 14503969
  46. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
    Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22 PMID: 12518065
  47. Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses.
    J Exp Med. 2003 Apr 7;197(7):927-32 PMID: 12668642
  48. Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors.
    Nat Biotechnol. 2003 Aug;21(8):932-5 PMID: 12845329
  49. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
    J Infect Dis. 2002 Oct 15;186(8):1065-73 PMID: 12355355
  50. Overcoming immunity to a viral vaccine by DNA priming before vector boosting.
    J Virol. 2003 Jan;77(1):799-803 PMID: 12477888
  51. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii.
    J Virol. 2003 Nov;77(21):11859-66 PMID: 14557672
  52. Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias.
    J Immunol. 2003 Mar 1;170(5):2599-604 PMID: 12594287
  53. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
    J Virol. 2004 Apr;78(8):3930-40 PMID: 15047809
  54. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
    Nat Med. 2003 Jun;9(6):729-35 PMID: 12766765
  55. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
    J Virol. 2003 Dec;77(24):13348-60 PMID: 14645590
  56. Ex vivo detection and enumeration of human antigen-specific CD8+ T lymphocytes using antigen delivery by a recombinant vaccinia expression vector and intracellular cytokine staining.
    J Immunol Methods. 2002 Apr 1;262(1-2):167-80 PMID: 11983230
  57. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    J Virol. 2002 Aug;76(15):7713-23 PMID: 12097585
Article Info
Journal
Current opinion in biotechnology
Abbr.
Curr Opin Biotechnol
ISSN
0958-1669
DOI
10.1016/j.copbio.2004.09.001
Published
2004-12-00
Pages
506-12
Language
English
Region
England
NLM ID
9100492
PMCID
PMC7127071
Subset
IM
External Links
PubMed source DOI: 10.1016/j.copbio.2004.09.001 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2